Literature DB >> 3734433

Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens.

P Suntharasamai, P Chanthavanich, M J Warrell, S Looareesuwan, J Karbwang, W Supanaranond, R E Phillips, W Jansawan, C Xueref, X Pouradier-Duteil.   

Abstract

Neutralizing antibody responses to conventional rabies post-exposure regimens of human diploid cell strain vaccine (HDCSV) and the new purified Vero cell rabies vaccine (PVRV) were compared in 58 healthy Thai veterinary students. The geometric mean titres (GMTs) of the group given HDCSV were slightly higher than those given PVRV, but on day 28 the peak GMTs of the two groups were statistically similar. The early antibody response to PVRV was unaffected by the addition of passive immunization, whereas the level of HDCSV response was reduced on day 14, so that there was no difference on that day between the GMTs of the two vaccine groups given HRIG. However, by day 91 the GMT of those given PVRV and HRIG was lower than in those given HDCSV alone or with HRIG. The appearance of antibody was less rapid than was observed in previous studies using multiple-site intradermal vaccination. Side effects were trivial. Our results confirm the promise of this new, potentially more economical tissue culture vaccine, but they suggest that the regimen could be improved.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734433      PMCID: PMC2129681          DOI: 10.1017/s0022172400066286

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  6 in total

1.  An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis.

Authors:  M J Warrell; D A Warrell; P Suntharasamai; C Viravan; A Sinhaseni; D Udomsakdi; R Phanfung; C Xueref; J C Vincent-Falquet; K G Nicholson; D Bunnag; T Harinasuta
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

2.  Possible factors influencing unsuccessful protection of post-exposure prophylaxis for rabies by human diploid cell vaccine.

Authors:  P Thongcharoen; C Wasi
Journal:  J Med Assoc Thai       Date:  1985-07

3.  Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis.

Authors:  M J Warrell; K G Nicholson; D A Warrell; P Suntharasamai; P Chanthavanich; C Viravan; A Sinhaseni; M K Chiewbambroongkiat; X Pouradier-Duteil; C Xueref
Journal:  Lancet       Date:  1985-05-11       Impact factor: 79.321

4.  Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens.

Authors:  M J Warrell; P Suntharasamai; K G Nicholson; D A Warrell; P Chanthavanich; C Viravan; A Sinhaseni; R Phanfung; C Xueref; J C Vincent-Falquet
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

5.  Failure to achieve predicted antibody responses with intradermal and intramuscular human diploid cell rabies vaccine.

Authors:  S M Lemon; R N Miller; L W Pang; R E Prier; K W Bernard
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

Review 6.  Rabies vaccine prepared in human cell cultures: progress and perspectives.

Authors:  S A Plotkin
Journal:  Rev Infect Dis       Date:  1980 May-Jun
  6 in total
  6 in total

1.  Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods.

Authors:  P M Kitala; K J Lindqvist; E Koimett; B K Johnson; C N Chunge; P Perrin; O Olsvik
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

2.  In pursuit of the perfect rabies vaccine.

Authors:  S D Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

3.  Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis.

Authors:  P Suntharasamai; M J Warrell; C Viravan; P Chanthavanich; S Looareesuwan; A Supapochana; J K Supanaranond; S Chittamas; U Bijok; D A Warrell
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

4.  Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India.

Authors:  Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayana Madhusudana; Gadey Sampath; Radhe Madhab Tripathy; Mysore Kalappa Sudarshan; Haradanahalli Shankaraiah Ravish; Durga Madhab Satapathy; Giriyanna Gowda; Ramesh Holla; Belludi Yajman Ashwin; Asutosh Padhi; Shamanna Manjula; Pradip Maganlal Patel
Journal:  Hum Vaccin Immunother       Date:  2013-09-12       Impact factor: 3.452

5.  Post-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies Infection.

Authors:  Sanne Terryn; Aurélie Francart; Heidi Rommelaere; Catelijne Stortelers; Steven Van Gucht
Journal:  PLoS Negl Trop Dis       Date:  2016-08-02

Review 6.  Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.

Authors:  Shimao Zhu; Caiping Guo
Journal:  Viruses       Date:  2016-10-28       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.